View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025  Aggregated presentation by day and by market  Statement of transactions in own shares from June 23rd to June 27th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market         (MIC Code) IPSEN 549300M6SGDPB4Z94P11 23/06/2025 FR0010259150    335    100,58955 AQEU   IPSEN 549300M6SGDPB4Z94P11 ...

 PRESS RELEASE

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2025 Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 23 juin au 27 juin 2025  Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code identifiant de l'instrument financier Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d'acquisition Code identifiant marché IPSEN 549300M6SGDPB4Z94P11 23/06/2025 FR0010259150    335    100,58955 AQEU IPSEN 549300M6SGDPB4Z94P11 23/06/20...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASR: Buyout deal, second in as many months, similar size (€660m). Flow Traders: Sticky digits. IMCD: Small but solid acquisition in India. Randstad: Preliminary preview of 2Q25F results due 23 July. UCB: Fintepla meets primary endpoint in CDKL5 Deficiency Disorder

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Gimv: Hear, hear – new acquisition. KBC: Now Belfius lowers saving rates to 0.60%

 PRESS RELEASE

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025  Aggregated presentation by day and by market               Statement of transactions in own shares from June 16th to June 20th 2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)  IPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   140   103,60AQEUIPSEN549300M6SGDPB4Z94P1116/06/2025FR0010259150   221   103,50CCXEIPSEN549300M6SGDPB4Z94P111...

 PRESS RELEASE

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2025  Présentation agrégée par jour et par marché           Déclaration des transactions sur actions propres réalisées du 16 juin au 20 juin 2025         Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code identifiant de l'instrument financier Volume total journalier (en nombre de titres) Prix pondéré moyen journalier d'acquisition Code identifiant marché IPSEN 549300M6SGDPB4Z94P11 16/06/2025 FR0010259150    140    103,60 AQEU   IPSEN 549300M6SGDPB...

 PRESS RELEASE

The Michelin Guide Expands Its Culinary Horizons to Saudi Arabia

The Michelin Guide Expands Its Culinary Horizons to Saudi Arabia The MICHELIN Guide announced its arrival in a new destination: Saudi Arabia, for an upcoming 2026 edition.The restaurant selection for the inaugural edition will be unveiled towards the end of the year 2025.The renowned anonymous MICHELIN Inspectors are already in the field, meticulously exploring the Kingdom's vibrant culinary scene. RIYADH, Saudi Arabia, June 24, 2025 (GLOBE NEWSWIRE) -- The MICHELIN Guide announced today its latest expansion into the vibrant culinary landscapes of Saudi Arabia. This new selecti...

 PRESS RELEASE

Ipsen receives positive CHMP opinion for Cabometyx® in previously trea...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Recommendation based on CABINET Phase III trial results, which demonstrated statistically significant and clinically meaningful reductions in risk of disease progression or death with Cabometyx versus placebo3,4European Commission decision expected Q3...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch